Company intelligence / Profile preview

Imdaptive

Seattle, Washington, United States

Ownership: Private
Development stage: Other

Overview

Imdaptive demonstrated the utility of advanced sequencing and bioinformatics for profiling antibody variable chain diversity in response to adjuvanted vaccines. Results contributed to published work on vaccine formulation and immune repertoire analysis but no clinical trials or marketed therapeutics were reported.

Therapeutic areas: Infectious Diseases
Modalities: Monoclonal antibodySequencing-based profiling
Industry: Drug Discovery Services

Partnerships

Infectious Disease Research Institute (IDRI)International Centre for Genetic Engineering and Biotechnology (ICGEB)

Beyond the preview

Go deeper on Imdaptive.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Imdaptive.

Explore the full profile